(51) International Patent Classification:
A61K 31/70 (2006.01)  A61K 31/07 (2006.01)
A61K 38/00 (2006.01)  A61K 31/202 (2006.01)

(21) International Application Number:
PCT/US20 17/032092

(22) International Filing Date:
11 May 2017 (11.05.2017)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
62/334,733  11 May 2016 (11.05.2016)  US

(71) Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; 1150 South Olive Street, Los Angeles, California 90015 (US).

(72) Inventors: LONGO, Valter D.; 8240 Zitola Terrace, Playa Del Rey, California 90293 (US).  CHOI, In Young; 1150 South Olive Street, Ste. 2300, Los Angeles, California 90015 (US).

(74) Agent: PROSCIA, James W. et al; Brooks Kushman, 1000 Town Center, Twenty-Second Floor, Southfield, Michigan 48075 (US).


Declarations under Rule 4.17:
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(1));
— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(2));
— with international search report (Art. 21(3)).

Published:
WO 2017/197076 A1

(54) Title: FASTING MIMICKING DIET (FMD) AS AN IMMUNOREGULATORY TREATMENT FOR GASTROINTESTINAL AUTOIMMUNE/INFLAMMATORY DISEASES.

(57) Abstract: A method for treating autoimmune and/or inflammatory diseases includes a step of identifying a subject having a gastrointestinal autoimmune/inflammatory disease. A fasting mimicking diet (FMD) is administered to the subject for a first time period.
FASTING MEVIICKING DIET (FMD) AS AN IMMUNOREGULATORY TREATMENT FOR GASTROINTESTINAL AUTOIMMUNE/INFLAMMATORY DISEASES.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. provisional application Serial No. 62/334,733 filed May 11, 2016, the disclosure of which is hereby incorporated in its entirety by reference herein.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] The invention was made with Government support under Contract No. P01AG034906 awarded by the National Institutes of Health/National Intelligence Authority. The Government has certain rights to the invention.

TECHNICAL FIELD

[0003] The present invention, in general, relates to methods for treating and reversing inflammatory bowel disease (IBD), which includes both Crohn's disease and ulcerative colitis, and other gastrointestinal autoimmune and inflammatory diseases in part by reducing, preventing, or reversing immune response of both innate and adaptive immunity and in part by promoting intestinal regeneration.

BACKGROUND

[0004] Autoimmune diseases involve a miscommunication between innate and adaptive immunity and an imbalance between T lymphocytes populations, which play critical roles in the immuno-pathogenesis of many autoimmune/chronic inflammatory diseases. It has been shown that both hyperactive innate immune response (i.e. macrophages and dendritic cells), imbalance between autoreactive associated effector cells (i.e. CD4+ Th1 and CD4+ Th17) and anti-inflammatory associated regulatory T cells (CD4+ Treg), and pro-inflammatory cytokine productions...
contribute to the pathogenesis of major gastrointestinal autoimmune/inflammatory diseases including Crohn's disease (CD), ulcerative colitis (UC), irritable bowel syndrome, celiac disease, microscopic colitis (collagenous and lymphocytic colitis), and Bejket disease \(^3\). See also Table 1 for comprehensive list of autoimmune/inflammatory diseases.\(^{59-11}\).

### [0005] Current therapies for gastrointestinal autoimmune/inflammatory diseases are monoclonal antibodies or a combination therapy with monoclonal antibody and immunomodulatory treatment; however the efficacy of the monoclonal or the combination therapy are still controversial and its long-term safety still remains to be investigated \(^{12-14}\). Moreover, the limitation in the number of efficacious monoclonal antibodies, infusion reactions, immunogenicity, high-cost, and adverse events such as lymphoma or acute anaphylaxis limit their applications \(^{15,16}\).

### [0006] Accordingly, there is a need for improved methods of treating autoimmune and/or inflammatory disease, and in particular for treating gastrointestinal autoimmune/inflammatory disease.

**SUMMARY**

### [0007] The present invention solves one or more problems of the prior art by providing a method for treating autoimmune and/or inflammatory disease. The method includes a step of administering a fasting mimicking diet (FMD) to the subject for a first time period to a subject having a gastrointestinal autoimmune and/or inflammatory disease.

### [0008] In another embodiment, a diet package for practicing the methods set forth herein is provided. The diet package includes a first set of rations for a first diet to be administered for a predetermined time period to a subject with administration schedule. The first diet providing less than 40 grams of sugar for day 1; less than 30 grams of sugar for days 2 to 5 and any remaining days; less than 28 grams of protein for day 1; less than 18 grams of protein for days 2 to 5 and any remaining days; 20-100 grams of monounsaturated fats for day 1; 6-30 grams of polyunsaturated fats for day 1; 2-12 grams of saturated fats for day 1; 10-50 grams of monounsaturated fats for days 2 to 5 and any remaining days; 3-15 grams of polyunsaturated fats for days 2 to 5 and any remaining days; 1-12 grams of saturated fats for days 2 to 5, or any remaining days; a micronutrient
composition on each day and any remaining days; and optionally instructions for administering the diet package to a subject for treating autoimmune and/or inflammatory disease. Characteristically, the instructions including the administration schedule.

**BRIEF DESCRIPTION OF THE DRAWINGS**

[0009] FIGURE 1. FMD reduced intestinal inflammation/colitis severity validated by Hemoccult test: The FMD treatment reduced fecal bleeding compare to the control diet treatment (Blue staining indicates a presence of fecal blood).

[0010] FIGURE 2. FMD increases endogenous corticosterone production. Corticosterone is a glucocorticoid hormone with broad anti-inflammatory and immunosuppressive effects affecting leukocyte distribution, trafficking, and death. The FMD treatment resulted in an increase corticosterone level compared to the control diet treatment.

[0011] FIGURE 3. Table 1: FMD-altered both innate and adaptive immune response and cytokines as therapeutic targets for treating major gastrointestinal autoimmune/inflammatory diseases.

[0012] FIGURE 4. Table 2: FMD prevented colon shortening. Shortening of the colon is classically associated with DSS induced colitis. The FMD treated group showed protection against the DSS-induced colon shortening compared to the control diet treated group (p < 0.01).

[0013] FIGURE 5. Table 3: FMD causes colon regeneration. Shortening of the colon is classically associated with DSS induced colitis. The FMD cycles applied after the colon was shortened by the IBD, caused a major increase in the colon length, indicating a strong regenerative effect (p < 0.01).

[0014] FIGURE 6. Table 4: FMD reduces innate immune response. The FMD reduced the number of dendritic cells and macrophages of innate immune system compared to the control.

[0015] FIGURE 7. Table 5: FMD reduces adaptive immune response. The FMD group reduced the number of B lymphocytes and autoimmune associated Th1 and Th17 lymphocytes
compared to the control diet group while it increased the anti-inflammatory regulatory T cells (Treg).

[0016] FIGURE 8. Table 6: FMD reduces autoimmune-associated cytokines productions (IFN-γ and IL-17) and increases an anti-inflammatory cytokine production (TL-10).

DETAILED DESCRIPTION

[0001] Reference will now be made in detail to presently preferred compositions, embodiments, and methods of the present invention which constitute the best modes of practicing the invention presently known to the inventors. The Figures are not necessarily to scale. However, it is to be understood that the disclosed embodiments are merely exemplary of the invention that may be embodied in various and alternative forms. Therefore, specific details disclosed herein are not to be interpreted as limiting, but merely as a representative basis for any aspect of the invention and/or as a representative basis for teaching one skilled in the art to variously employ the present invention.

[0002] Except in the examples, or where otherwise expressly indicated, all numerical quantities in this description indicating amounts of material or conditions of reaction and/or use are to be understood as modified by the word "about" in describing the broadest scope of the invention. Practice within the numerical limits stated is generally preferred. Also, unless expressly stated to the contrary: percent, "parts of," and ratio values are by weight; the description of a group or class of materials as suitable or preferred for a given purpose in connection with the invention implies that mixtures of any two or more of the members of the group or class are equally suitable or preferred; description of constituents in chemical terms refers to the constituents at the time of addition to any combination specified in the description, and does not necessarily preclude chemical interactions among the constituents of a mixture once mixed; the first definition of an acronym or other abbreviation applies to all subsequent uses herein of the same abbreviation and applies mutatis mutandis to normal grammatical variations of the initially defined abbreviation; and, unless expressly stated to the contrary, measurement of a property is determined by the same technique as previously or later referenced for the same property.
The term "comprising" is synonymous with "including," "having," "containing," or "characterized by." These terms are inclusive and open-ended and do not exclude additional, unrecited elements or method steps.

The phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. When this phrase appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element set forth in that clause; other elements are not excluded from the claim as a whole.

The phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps, plus those that do not materially affect the basic and novel characteristic(s) of the claimed subject matter.

It is also to be understood that this invention is not limited to the specific embodiments and methods described below, as specific components and/or conditions may, of course, vary. Furthermore, the terminology used herein is used only for the purpose of describing particular embodiments of the present invention and is not intended to be limiting in any way.

It must also be noted that, as used in the specification and the appended claims, the singular form "a," "an," and "the" comprise plural referents unless the context clearly indicates otherwise. For example, reference to a component in the singular is intended to comprise a plurality of components.

Throughout this application, where publications are referenced, the disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

The terms "kilocalorie" (kcal) and "Calorie" refer to the food calorie. The term "calorie" refers to the so-called small calorie.
The term "fasting mimicking diet" (FMD) means a diet that mimics the effects of fasting typically by providing a subject with at most 50% of their normal caloric intake but with some nutritional component so that fasting is mimicked while a subject is not completely starved. Examples of useful fasting mimicking and enhancing diets and method for monitoring the effects of these diets on markers such as IGF-1 and IGFBP1 in the context of the present invention are set forth in U. S. Pat. Appl. Nos. 14/273946 filed May 9, 2014; 14/497752 filed September 26, 2014; 12/910508 filed October 22, 2010; 13/643673 filed October 26, 2012; 13/982307 filed July 29, 2013; 14/060494 filed October 22, 2013; 14/178953 filed February 12, 2014; 14/320996 filed July 1, 2014; 14/671622 filed March 27, 2015; the entire disclosure of these patent applications is hereby incorporated by reference. The fasting mimicking diet set forth in U.S. Pat. Appl. Nos. 14/060494 and 14/178953 are found to be particularly useful in the present invention. Additional examples of FMD diets are found in U.S. Pat. Appl. No. 15148251 and WIPO Pub. No. WO201 1/050302 and WIPO Pub. No. WO2011/050302; the entire disclosures of which are hereby incorporated by reference.

The present invention solves one or more problems of the prior art by providing in at least on embodiment, a method for treating autoimmune and/or inflammatory disease. The method includes a step of identifying a subject having a gastrointestinal autoimmune/inflammatory disease. A fasting mimicking diet (FMD) is administered to the subject for a first time period. Typically, the administration of the FMD is repeated a plurality of times at predetermined intervals. In a refinement, the FMD is repeated at intervals from one week to 6 months. In some variations, a normal diet is administered between cycles of the FMD. In this context, a normal diet is a diet of sufficient caloric intake to maintain the subject's weight. In a refinement, the normal caloric intake provides the subject with 1500 to 2500 kcal or 1800 to 2300 kcal, or 1800 to 2000 kcal.

The FMD is administered to the subject for a first time period. In some variations, the first time period is equal to or greater than, in increasing order of preference, 3, 5, 6, or 7 days. In addition, the first time period is equal to or less than, in increasing order of preference, 20, 15, 10, or 8 days. In a refinement, the first time period 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days. In another refinement, the first time period is 5 to 10 days. In some variations of the methods set forth herein, the fasting mimicking and enhancing diet is repeated at first intervals. For example, the fasting
mimicking and enhancing diet can be initiated once a month for the duration of the subject's treatment which can be 3 months to a year or more (e.g., 1 to 5 years).

In some variations, the fasting mimicking diet for each of the methods set forth herein provides at most, in increasing order of preference, 50%, 40%, 30%, or 100% of the subject's normal caloric intake. In a refinement, the fasting mimicking diet provides at least, in increasing order of preference, 5%, 10%, or 20% of the subject's normal caloric intake. The subject's normal caloric intake is the number of kcal that the subject consumes to maintain his/her weight. The subject's normal caloric intake may be estimated by interviewing the subject or by consideration of a subject's weight. As a rough guide, subject's normal caloric intake is on average 2600 kcal/day for men and 1850 kcal/day for women. In certain instances, the fasting mimicking diet provides the subject with from 700 to 1200 kcal/day. In a particularly useful refinement, the fasting mimicking diet provides a male subject of average weight with at most 1100 kcal/day and a female subject of average weight with at most 900 kcal/day. In some refinements, the fasting mimicking diet provides at most, in increasing order of preference, 1500 kcal/day, 1400 kcal/day, 1300 kcal/day, 1200 kcal/day, 1100 kcal/day, 1000 kcal/day, 900 kcal/day, 800 kcal/day, 700 kcal/day, 600 kcal/day, 500 kcal/day, or 2500 kcal/day. In some further refinements, the fasting mimicking diet provides at least, in increasing order of preference, 0 kcal/day, 10 kcal/day, 100 kcal/day, 200 kcal/day, 300 kcal/day, 400 kcal/day, or 500 kcal/day.

In certain variations, the fasting mimicking and enhancing diet provides from 4.5 to 7 kilocalories per pound of subject for a first day (day 1) and then 3 to 5 kilocalories per pound of subject per day for the second to the final day. After a cycle of the fasting mimicking and enhancing diet, a second diet is administered to the subject for a second time period. In a refinement, the second diet provides an overall calorie consumption that is within 20 percent of a subject's normal calorie consumption for 10 to 26 days (e.g., immediately) following the fasting mimicking and enhancing diet.

The consumption guidelines for the FMD include Nutrition Facts relative to calories, macronutrients and micronutrients. Calories are consumed according to the user's body weight. Total calorie consumption is 4.5-7 calorie per pound (or 10-16 calorie per kilogram) for day 1 and 3-5 calorie per pound (or 7-11 calorie per kilogram) for day 2 to 5 and any remaining days. In a
variation of the embodiments set forth above, the fasting mimicking diet provides less than 40 grams of sugar for day 1, less than 30 grams of sugar for days 2 to 5 and any remaining days, less than 28 grams of protein for day 1, less than 18 grams of protein for days 2 to 5 and any remaining days, 20-100 or 20-30 grams of monounsaturated fats or more to reach a higher calorie consumption (i.e., to reach a higher predetermined calorie consumption) for day 1, 6-30 or 6-10 grams of polyunsaturated fats or more to reach a higher calorie consumption for day 1, 2-12 grams of saturated fats or more to reach a higher calorie consumption for day 1, 10-50 or 10-15 grams of monounsaturated fats or more to reach a higher calorie consumption for days 2 to 5 and any remaining days, 3-15 or 3-5 grams of polyunsaturated fats or more to reach a higher calorie consumption for days 2 to 5 and any remaining days, 1-12 or 1-6 grams of saturated fats or more to reach a higher calorie consumption for days 2 to 5, or any remaining days, and a micronutrient composition on each day and any remaining days. To reach the higher calorie consumption described earlier which can be as high as a normal calorie intake, equal parts of the fats described above and of vegetable derived carbohydrate sources (vegetable soups and chips) described elsewhere in the patent can be used. A FMD with calories ranging from 50% restricted to normal, is expected to be effective but less effective than the 50% or more restricted diet described in this application.

[0027] In another variation of the embodiments set forth above, the fasting mimicking diet provides 8-10 kcal per kilogram body weight for each diet day. In this variation, the fasting mimicking diet provides less than 30 grams of sugar for each diet day, less than 18 grams of protein for each diet day, 9-15 grams of monounsaturated fats for each diet day, and 2.5-4.5 grams of polyunsaturated fats for each diet day and 1.5-5.5 grams of saturated fats for each diet day.

[0028] In still another variation of the embodiments set forth above, the fasting mimicking diet provides 5-8 kcal per kilogram body weight for each diet day. In this variation, the fasting mimicking diet provides less than 20 grams of sugar for each diet day, less than 12 grams of protein for each diet day, and 6.5-10 grams of monounsaturated fats for each diet day, 2.5-4.5 grams of polyunsaturated fats for each diet day and 1.5-4 grams of saturated fats for each diet day.

[0029] In still another variation of the embodiments set forth above, the fasting mimicking diet provides 0-3 kcal per kilogram body weight for each diet day. In this variation, the fasting mimicking diet provides less than 5 grams of sugar for each diet day, less than 3 grams of protein for
each diet day, and less than 2.5 grams of monounsaturated fats for each diet day, less than 1 grams of polyunsaturated fats for each diet day and less than 1 grams of saturated fats for each diet day.

[0030] The fast mimicking diet can include virtually any source of fat, but sources high in unsaturated fat, including monounsaturated and polyunsaturated fat sources, are particularly useful. Suitable examples of monounsaturated food sources include, but are not limited to, peanut butter, olives, nuts (e.g., almonds, pecans, walnut, pistachios, cashews, macadamia), avocado, seeds (e.g., sesame), oils (e.g., olive, sesame, peanut, canola), etc. Suitable examples of polyunsaturated food sources include, but are not limited to, walnuts, seeds (e.g., pumpkin, sunflower), flaxseed, fish (e.g., salmon, tuna, mackerel), oils (e.g., safflower, soybean, corn). The first diet also includes a component selected from the group consisting of vegetable extracts, minerals, omega-3/6 essential fatty acids, and combinations thereof. In one refinement, such a vegetable extract provides the equivalent of 5 recommended daily servings of vegetables. Suitable sources for the vegetable extract include, but are not limited to, bokchoy, kale, lettuce, asparagus, carrot, butternut squash, alfalfa, green peas, tomato, cabbage, cauliflower, beets. Suitable sources for the omega-3/6 essential fatty acids include fish such as salmon, tuna, mackerel, bluefish, swordfish, and the like.

[0031] In a variation, the fasting mimicking diet includes the following micronutrients (at least 95% non-animal based): over 5,000 IU of vitamin A per day (day 1 to the final day); 60-240 mg of vitamin C per day (day 1 to the final day); 400-800 mg of Calcium per day (day 1 to the final day); 7.2-14.4 mg of Iron per day (day 1 to the final day); 200-400 mg of Magnesium per day (day 1 to the final day); 1-2 mg of copper per day (day 1 to the final day); 1-2 mg of Manganese per day (day 1 to the final day); 3.5-7 mg of Selenium per day (day 1 to the final day); 2-4 mg of Vitamin B1 per day (day 1 to the final day); 2-4 mg of Vitamin B2 per day (day 1 to the final day); 10-30 mg of Vitamin B3 per day (day 1 to the final day); 1.5 mg of Vitamin B5 per day (day 1 to the final day); 2-4 mg of Vitamin B6 per day (day 1 to the final day); 240-480 mg of Vitamin B9 per day (day 1 to the final day); 600-1000 IU of Vitamin D per day (day 1 to the final day); 14-30 mg of Vitamin E per day (day 1 to the final day); over 80 mg of Vitamin K per day (day 1 to the final day); 16-25 mg Vitamin B12 are provided during the entire 5-day period; 600 mg of Docosahexaenoic acid (DHA, algae-derived) are provided during the entire 5-day period. The FMED diet provides high micronutrient content mostly (i.e., greater than 50 percent by weight) from natural sources including: Kale, Cashews, Yellow Bell Pepper, Onion, Lemon Juice, Yeast, and
Turmeric, Mushroom, Carrot, Olive Oil, Beet Juice, Spinach, Tomato, Collard, Nettle, Thyme, Salt, Pepper, Vitamin B12 (Cyanocobalamin), Beets, Butternut Squash, Collard, Tomato, Oregano, Tomato Juice, Orange Juice, Celery, Romaine Lettuce, Spinach, Cumin, Orange Rind, Citric Acid, Nutmeg, Cloves, and combinations thereof. Table 1 provides an example of additional micronutrient supplementation that can be provided in the FMD diet:

[0032] In some variations, a second diet is administered to the subject for a second time period. The second diet provides an overall calorie consumption that is within 10 percent of a subject's normal calorie consumption. Although the present invention is not significantly limited by the second time period, the second time period can be from 7 days to 6 months or longer. Typically, the second diet can be administered for 25 to 26 days or longer following the fasting mimicking and enhancing diet. In some refinements, the second diet provides at most, in increasing order of preference, 2500 kcal/day, 2400 kcal/day, 2300 kcal/day, 2200 kcal/day, 2100 kcal/day, 2000 kcal/day, 1900 kcal/day, 1800 kcal/day, 1700 kcal/day, 1600 kcal/day, or 1500 kcal/day. In some further refinements, the second diet provides at least, in increasing order of preference, 1200 kcal/day, 1300 kcal/day, 1400 kcal/day, 1500 kcal/day, 1600 kcal/day, 1700 kcal/day, or 1800 kcal/day.

[0033] In another embodiment, a diet package for treating autoimmune and/or inflammatory disease is provided. In a variation, the diet includes the caloric, food and nutritional specification set forth above in accordance to the methods and administration schedule set forth above. For example, the diet package includes a first set of rations for a first diet to be administered for a predetermined time period to a subject with administration schedule. The first diet providing less than 40 grams of sugar for day 1; less than 30 grams of sugar for days 2 to 5 and any remaining days; less than 28 grams of protein for day 1; less than 18 grams of protein for days 2 to 5 and any remaining days; 20-100 or 20-30 grams of monounsaturated fats or more to reach the higher calorie intake for day 1; 6-30 or 6-10 grams of polyunsaturated fats or more to reach the higher calorie intake for day 1; 2-12 grams of saturated fats or more to reach the higher calorie intake for day 1; 10-50 or 10-15 grams of monounsaturated fats or more to reach the higher calorie intake for days 2 to 5 and any remaining days; 3-15 or 3-5 grams of polyunsaturated fats or more to reach the higher calorie intake for days 2 to 5 and any remaining days; 1-30 or 1-6 grams of saturated fats or more to reach the higher calorie intake for days 2 to 5, or any remaining days; and a micronutrient composition on each day and any...
remaining days. In a refinement, the diet package also includes instructions for administering the fasting mimicking diet in accordance to the methods herein, and in particular, instructions for administering the diet package to a subject for treating autoimmune and/or inflammatory disease the instructions including the administration schedule. To reach the higher calorie consumption described earlier which can be as high as a normal calorie intake, equal parts of the fats described above and of vegetable derived carbohydrate sources (vegetable soups and chips) described elsewhere in the patent can be used. A FMD with calories ranging from 50% restricted to normal, is expected to be effective but less effective than the 50% or more restricted diet described in this application.

[0034] In a variation, the fasting mimicking diet of the diet package provides 8-25 or 8-10 kcal per kilogram body weight for each diet day; less than 30 grams of sugar for each diet day; less than 18 grams of protein for each diet day; and 9-30 or 9-15 grams of monounsaturated fats for each diet day, 2.5-9 or 2.5-4.5 grams of polyunsaturated fats for each diet day and 1-10 or 1-5.5 grams of saturated fats for each diet day. In another variation, the fasting mimicking diet of the diet package provides 5-8 kcal per kilogram body weight for each diet day; less than 20 grams of sugar for each diet day; less than 12 grams of protein for each diet day; and 6.5-10 grams of monounsaturated fats for each diet day, 2.5-4.5 grams of polyunsaturated fats for each diet day and 1.5-4 grams of saturated fats for each diet day. In still another variation, the diet package provides 0-3 kcal per kilogram body weight for each diet day; less than 5 grams of sugar for each diet day; less than 3 grams of protein for each diet day; and less than 2.5 grams of monounsaturated fats for each diet day, less than 1 grams of polyunsaturated fats for each diet day and less than 1 grams of saturated fats for each diet day.

[0035] The first set of rations can also provide 400-800 mg of calcium per day for days 1-5; 7.2-14.4 mg of iron per day for days 1-5; 200-400 mg of magnesium per day for days 1-5; 1-2 mg of copper per day for days 1-5; 1-2 mg of manganese per day for days 1-5; and 3.5-7 mg of selenium per day for days 1-5. In a refinement, the first set of rations provides 2-4 mg of Vitamin B1 per day for days 1-5; 2-4 mg of Vitamin B2 per day for days 1-5; 20-30 mg of Vitamin B3 per day for days 1-5; 1-1.5 mg of Vitamin B5 per day for days 1-5; 2-4 mg of Vitamin B6 per day for days 1-5; 240-480 meg of Vitamin B9 per day for days 1-5; 600-1000 IU of Vitamin D per day for days 1-5; 14-30 mg of Vitamin E per day for days 1-5; over 80 meg of Vitamin K per day for days 1-5; and 16-25
meg Vitamin B12 are provided during the predetermined time period. In a further refinement, the first set of rations provides 600 mg of Docosahexaenoic acid (DHA, algae-derived) during the predetermined time period. In a refinement the first set of rations also provides a component having Vitamin A in an amount of 900-1600 IU; Ascorbic Acid in an amount of 10-20 mg; calcium carbonate in an amount of 60-100 mg; ferrous fumarate in an amount of 3-6 mg; cholecalciferol in an amount of 0.001-0.005 mg; dl-alpha tocopheryl acetate in an amount 3-7 mg; phytonadione in an amount of 0.1-0.04 mg; thiamine mononitrate in an amount of 0.15-0.5 mg; riboflavin in an amount 0.2-0.6 mg; and niacinamide in an amount of 3-7mg. In a refinement the first set of rations also provides a component having calcium pantothenate in an amount of 1.5-4.0 mg; pyridoxine hydrochloride in an amount of 0.3-0.7 mg; biotin in an amount of 0.01-0.02 mg; folic acid in an amount of 0.07-0.14 mg; cyanocobalamin in an amount of 0.001-0.002 mg; chromium picolinate in an amount of 0.014-0.022 mg; cupric sulfate in an amount of 0.18-0.32 mg; potassium iodide in an amount of 0.03-0.045 mg; magnesium oxide in an amount of 20-32 mg; manganese sulfate of 0.3-0.7 mg; sodium molybdate in an amount of 0.014-0.023 mg; sodium selenate in an amount of 0.014-0.023 mg; and zinc oxide in an amount of 3-5 mg.

[0036] In some variations, the diet package includes a second set of rations for a second diet to be administered to the subject for a second time period. The second diet providing an overall calorie consumption that is within 10 percent of a subject's normal calorie consumption for 25 to 26 days following the first diet. In particular, the second diet provides the caloric, food and nutritional specification for a subject's normal diet as set forth above.

[0037] A particularly useful version of the fasting mimicking diet is disclosed in U.S. Pat. Appl. No. 15/432803 filed on February 14, 2017; the entire disclosure of which is hereby incorporated by references. In particular, a diet package with certain specific meal components for implementing a fasting mimicking diet in the method set forth herein is provided. In a refinement, the diet package also includes instruction for administering the fasting mimicking diet in accordance to the methods herein, and in particular, instructions for administering the diet package to a subject for treating autoimmune and/or inflammatory disease with the instructions including the administration schedule. In one variation, the fasting mimicking diet package and its associated fasting mimicking diet provide daily meal portions for a predetermined number of days are set forth above (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days). The fasting mimicking diet package includes a kale
cracker composition, a first vegetable broth composition, a mushroom soup composition, a tomato
soup composition, a quinoa-containing minestrone soup composition, a bean-containing minestrone
soup composition, and a pumpkin soup composition. Characteristically, the daily meal portions are
packaged into meal servings or into a total daily serving to be divided into meals. In a refinement,
the fasting mimicking diet package and its associated fasting mimicking diet further includes a nut-
containing nutrition bar, a cocoa-containing nutrition bar, a first olive-containing composition, a first
vegetable broth composition, a tea composition that includes spearmint, a energy drink composition,
a micronutritional composition, and an algal oil composition. In a further refinement, the fasting
mimicking diet package and its associated fasting mimicking diet further includes a second olive-
containing composition, a second vegetable broth composition, a tea composition that includes
spearmint and lemon, and a tea composition that includes hibiscus. It should be appreciated that
each of the soup, broth, tea and energy compositions set forth herein are designed to have added
water when consumed.

[0038 ] In another variation of a fasting mimicking diet package, diet package includes a nut-
containing nutrition bar, a cocoa-containing nutrition bar, a first olive-containing composition, a kale
cracker composition, a vegetable soup composition, a first vegetable broth composition, a tea
composition that includes spearmint, a energy drink composition, a micronutritional composition,
and a algal oil composition. Characteristically, the daily meal portions are packaged into meal
servings or into a total daily serving to be divided into meals. This diet package also includes daily
meal portions for a predetermined number of days as set forth above with the daily meal portions
being packaged into meal servings or into a total daily serving to be divided into meals. In a
refinement, the fasting mimicking diet package further includes a mushroom soup composition, a
tomato soup composition, a quinoa-containing minestrone soup composition, and a pumpkin soup
composition. In a further refinement, the fasting mimicking diet package further includes a second
olive-containing composition, a second vegetable broth composition, a bean-containing minestrone
soup composition, a tea composition that includes spearmint and lemon, and a tea composition that
includes hibiscus.

[0039 ] As set forth above, the fasting mimicking diet packages includes specific meal
components that are administered for the fasting mimicking diet. Typically, compositions are as
follows. The nut-containing nutrition bar includes almond meal and macadamia nuts. The cocoa-
containing nutrition bar includes almond butter, almonds, and brown rice crispy (e.g., brown puffed rice). The mushroom soup composition includes brown rice powder, carrots, inulin, and mushrooms. The bean-containing minestrone soup composition includes white beans, cabbage, and mushrooms. The first vegetable broth composition includes carrots, maltodextrin, celery, spinach, and tomatoes. The second vegetable broth composition includes carrots, maltodextrin, celery, spinach, soy lecithin, and tomatoes. The energy drink composition includes glycerin and water. The algal oil composition includes schizocatmum algae oil. The micronutrient composition includes beet root powder, calcium carbonate, carrots, collard leaf, kale leaf, and tomatoes. In a refinement, the micronutrient composition includes Vit A, Vit C, Ca, Fe, Vit D3, Vit E, Vit K, Vit Bl, Vit B2, Vit B3, Vit B5, Vit B6, Vit B7, Vit B9, Vit B12, Cr, Cu, I, Mg, Mn, Mo, Se, and Zn.

[0040] In a refinement, the nut-containing nutrition bar (L-Bar Nut based) includes almond meal and macadamia nuts. In a refinement, the nut-containing nutrition bar (L-Bar Nut based) includes almond meal preferably in an amount of 20 to 35 weight %; coconut preferably in an amount of 2 to 10 weight %; coconut oil preferably in an amount of 1 to 8 weight %; flax seed meal preferably in an amount of 1 to 8 weight %; honey preferably in an amount of 10 to 30 weight %; macadamia nuts preferably in an amount of 10 to 30 weight %; pecans preferably in an amount of 10 to 25 weight %; salt preferably in an amount of 0.1 to 0.8 weight %; and optionally vanilla preferably in an amount of 0.3 to 1.5 weight %.

[0041] In a refinement, the cocoa-containing nutrition bar (L-Bar ChocoCrisp) includes almond butter, almonds, and brown rice crispy (PGP 10235). In a refinement, the cocoa-containing nutrition bar (L-Bar ChocoCrisp) includes almond butter preferably in an amount of 10 to 25 weight %; almonds preferably in an amount of 3 to 12 weight %; brown rice crispy (PGP 10235) preferably in an amount of 10 to 25 weight %; brown rice syrup preferably in an amount of 2 to 8 weight %; chocolate liquor preferably in an amount of 1 to 4 weight %; cocoa butter preferably in an amount of 0.4 to 1.6 weight %; cocoa powder preferably in an amount of 4 to 12 weight %; fiber syrup SF75 preferably in an amount of 18 to 38 weight %, flax seed oil preferably in an amount of 1 to 3 weight %; salt preferably in an amount of 0.1 to 0.4 weight % and sugar preferably in an amount of 1 to 6 weight %.
In a refinement, the first olive-containing composition (sea salt version) includes olives, olive oil, and sea salt. In a refinement, the first olive-containing composition (sea salt) includes lactic acid preferably in an amount of 0.3 to 1 weight %; oil (olive) preferably in an amount of 2 to 6 weight %; olives (raw, green pitted) preferably in an amount of 50 to 97 weight %; salt (reg., kosher, sea salt) preferably in an amount of 0.8 to 3 weight %; and thyme preferably in an amount of 0.1 to 0.5 weight %.

In a refinement, the second olive-containing composition (garlic version) includes olives, olive oil, and garlic. In a refinement, the second olive-containing composition (garlic) includes garlic preferably in an amount of 0.1 to 0.6 weight %; lactic acid preferably in an amount of 0.3 to 1 weight %; oil (olive) preferably in an amount of 2 to 6 weight %; olives (raw, green pitted) preferably in an amount of 50 to 97 weight %; salt (reg., kosher, sea salt) preferably in an amount of 0.8 to 3 weight %; thyme preferably in an amount of 0.1 to 0.5 weight %.

In a refinement, the kale cracker composition includes kale, almonds, tapioca flour, and optionally sesame seeds. In another refinement, the kale cracker composition includes almonds preferably in an amount of 15 to 40 weight %; black pepper preferably in an amount of 0.1 to 0.4 weight %; chia seeds preferably in an amount of 3 to 10 weight %; chili pepper preferably in an amount of 0.4 to 1.2 weight %; cumin seeds preferably in an amount of 0.3 to 0.9 weight %; flax seeds preferably in an amount of 3 to 10 weight %; garlic preferably in an amount of 0.02 to 0.04 weight %; kale preferably in an amount of 2 to 6 weight %; oil (sunflower) preferably in an amount of 2 to 7 weight %; onion (powder, minced) typically in an amount of 0.3 to 0.9 weight %; oregano preferably in an amount of 0.01 to 0.06 weight %; salt preferably in an amount of 1 to 4 weight %; sesame seeds preferably in an amount of 15 to 35 weight %; sugar (coconut) preferably in an amount of 1 to 5 weight %; tapioca flour preferably in an amount of 10 to 30 weight %; vinegar (coconut) preferably in an amount of 1 to 4 weight %; water (purified) preferably in an amount of 2 to 12 weight %; and yeast extract preferably in an amount of 0.3 to 1 weight %.

In another refinement, the kale cracker composition includes kale, flax seeds golden, sesame seeds, and sunflower seeds. In another refinement, the apple cider vinegar preferably in an amount of 1 to 3 weight %; black pepper preferably in an amount of 0.4 to 1.3 weight %; cashews preferably in an amount of 4 to 13 weight %; dill weed preferably in an amount of 0.4 to 1.3 weight...
%; flax seeds golden preferably in an amount of 13 to 40 weight %; hemp seeds preferably in an amount of 0.7 to 2 weight %; kale preferably in an amount of 14 to 42 weight %; onion, white, dried, (powder, minced) preferably in an amount of 0.5 to 1.6 weight %; pumpkin seeds preferably in an amount of 0.7 to 2 weight %; salt (reg., kosher, sea salt) preferably in an amount of 0.7 to 2 weight %; Sesame seeds preferably in an amount of 2 to 8 weight %; sunflower seeds preferably in an amount of 10 to 30 weight %; and yeast extract preferably in an amount of 1 to 5 weight %.

[0046] In a refinement, the vegetable soup composition includes onions, tomatoes, spinach, green tree extract, optionally rice flour, optionally brown rice powder, optionally carrots, and optionally inulin, leeks. In a refinement, the vegetable soup composition includes basil (whole leaf, dried) preferably in an amount of 0.3 to 0.9 weight %; brown rice powder (whole grain) preferably in an amount of 3 to 12 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 4 to 14 weight %; green tea extract preferably in an amount of 0.02 to 0.06 weight %; inulin preferably in an amount of 5 to 15 weight %; leeks (granules -10+40) preferably in an amount of 1 to 5 weight %; oil (olive) preferably in an amount of 1 to 6 weight %; onion (powder, minced) preferably in an amount of 4 to 15 weight %; parsley preferably in an amount of 0.3 to 0.8 weight %; red bell peppers preferably in an amount of 1 to 5 weight %; rice flour preferably in an amount of 18 to 50 weight %; salt preferably in an amount of 2 to 7 weight %; spinach (leaf, powder) preferably in an amount of 0.4 to 1.5 weight %; tomatoes (fruit powder, sun dried, granules) preferably in an amount of 4 to 14 weight %; yeast extract preferably in an amount of 0.5 to 1.8 weight %. In the vegetable soup composition and any of the compositions set forth herein having rice flour, the rice flour can be glutinous or non-glutinous, milled or unmilled.

[0047] In another refinement, the vegetable soup composition includes carrots, inulin, leeks, onions and rice flour. In a refinement, the vegetable soup composition includes basil, whole leaf, dried preferably in an amount of 0.3 to 1 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 4 to 12 weight %; inulin preferably in an amount of 6 to 18 weight %; leeks in an amount of 1 to 5 weight %; oil (olive) preferably in an amount of 1 to 3 weight %; Onion, white, dried, (powder, minced) preferably in an amount of 10 to 30 weight %; parsley preferably in an amount of 0.3 to 1 weight %; potato preferably in an amount of 1 to 5 weight %; red pepper preferably in an amount of 1 to 6 weight %; rice flour in an amount of 13 to 40 weight %; salt (reg., kosher, sea salt) in an amount of 4 to 12 weight %; spinach (leaf, powder) preferably in an amount of
amount of 0.2 to 1 weight %; and tomatoes, (fruit powder, sun dried granules) preferably in an amount of 3 to 13 weight %.

[0048] In a refinement, the mushroom soup composition includes mushrooms, green tea extract, optionally brown rice powder, optionally carrots, and optionally inulin. In a refinement, the mushroom soup composition includes brown rice powder (whole grain) preferably in an amount of 10 to 30 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 3 to 12 weight %; green tea extract preferably in an amount of 0.02 to 0.06 weight %; inulin preferably in an amount of 3 to 12 weight %; mushrooms (European mix, powder, pieces) preferably in an amount of 6 to 18 weight %; oil (olive) preferably in an amount of 1 to 6 weight %; onion preferably in an amount of powder, minced) preferably in an amount of 3 to 12 weight %; parsley preferably in an amount of 0.1 to 0.5 weight %; rice flour preferably in an amount of 18 to 50 weight %; salt preferably in an amount of 2 to 8 weight %; yeast extract preferably in an amount of 0.5 to 1.5 weight %.

[0049] In another refinement, the mushroom soup composition includes carrots, inulin, mushrooms, onions, and rice flour. In another refinement, the mushroom soup composition includes carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 7 to 22 weight %; inulin preferably in an amount of 7 to 22 weight %; mushrooms (European mix), (powder & pieces) dehydrated preferably in an amount of 7 to 22 weight %; oil (olive) preferably in an amount of 0.6 to 2 weight %; Onion, white, dried, (powder, minced) preferably in an amount of 7 to 22 weight %; parsley preferably in an amount of 0.3 to 0.9 weight %; potato preferably in an amount of 0.6 to 2 weight %; rice flour preferably in amount of 15 to 45 weight %; salt (reg., kosher, sea salt) preferably in an amount of 6 to 18 weight %; and yeast extract preferably in an amount of 0.7 to 2.2 weight %.

[0050] In a refinement, the tomato soup composition includes tomatoes, green tea extract, optionally inulin, and optionally onions. In a refinement, the tomato soup composition (new) includes basil (whole leaf, dried) preferably in an amount of 0.2 to 0.7 weight %; brown rice powder (whole grain) preferably in an amount of 1 to 5 weight %; green tea extract preferably in an amount of 0.02 to 0.06 weight %; inulin preferably in an amount of 7 to 20 weight %; oil (olive) preferably in an amount of 3 to 9 weight %; onion preferably (powder, minced) preferably in an amount of 4 to
12 weight %; parsley preferably in an amount of 0.1 to 0.6 weight %; rice flour preferably in an amount of 18 to 50 weight %; salt preferably in an amount of 2 to 9 weight %; tomatoes (fruit powder, sun dried, granules) preferably in an amount of 2 to 8 weight %; zucchini (powder, diced) preferably in an amount of 0.1 to 0.6 weight %; rice flour preferably in an amount of 18 to 2 weight %; zucchini (powder, diced) preferably in an amount of 2 to 8 weight %.

[0051] In another refinement, the tomato soup composition includes tomatoes, inulin, olives, onions, potatoes, and rice flour. In still another refinement, the tomato soup composition includes basil, whole leaf, dried preferably in an amount of 0.3 to 1 weight %; inulin preferably in an amount of 6 to 18 weight %; oil (olive) preferably in an amount of 4 to 14 weight %; onion, white, dried, (powder, minced) preferably in an amount of 8 to 24 weight %; parsley preferably in an amount of 0.3 to 0.9 weight %; potato preferably in an amount of 6 to 18 weight %; rice flour preferably in an amount of 9 to 27 weight %; salt (reg., kosher, sea salt) preferably in an amount of 4 to 14 weight %; tomatoes, (fruit powder, sun dried granules) preferably in an amount of 8 to 24 weight %; and yeast extract preferably in an amount of 0.7 to 2.2 weight %.

[0052] In a refinement, the quinoa-containing minestrone soup composition includes quinoa, green tea extract, optionally olive oil, optionally cabbage, optionally potatoes, optionally rice flour, and optionally tomatoes and optionally no tumeric. In a refinement, the quinoa-containing minestrone soup composition includes basil (whole leaf, dried preferably in an amount of 0.7 to 2 weight %; broccoli powder preferably in an amount of 0.6 to 2 weight %; cabbage white (flakes) preferably in an amount of 3 to 10 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 3 to 10 weight %; celery preferably in an amount of 1 to 4 weight %; celery seeds (powder) preferably in an amount of 0.07 to 0.2 weight %; garlic preferably in an amount of 0.7 to 2 weight %; green tea extract preferably in an amount of 0.02 to 0.06 weight %; inulin preferably in an amount of 1 to 5 weight %; leeks (granules -10+40), preferably in an amount of 0.7 to 2 weight %; oil (olive) preferably in an amount of 0.6 to 2 weight %; onion (powder, minced) preferably in an amount of 2 to 8 weight %; peas preferably in an amount of 3 to 10 weight %; potato preferably in an amount of 7 to 20 weight %; quinoa preferably in an amount of 7 to 20 weight %; rice flour preferably in an amount of 7 to 20 weight %; salt, preferably in an amount of 1 to 6 weight %; spinach (leaf, powder) preferably in an amount of 0.5 to 2 weight %; tomatoes (fruit powder, sun dried, granules) preferably in an amount of 2 to 6 weight %; yeast extract preferably in an amount of 0.6 to 2 weight %; zucchini (powder, diced) preferably in an amount of 2 to 8 weight %.
[0053] In another refinement, the quinoa-containing minestrone soup includes quinoa, cabbage, potatoes, and rice flour. In still another refinement, the quinoa-containing minestrone soup includes basil, whole leaf, dried preferably in an amount of 0.7 to 2.2 weight %; broccoli powder preferably in an amount of 0.7 to 2.2 weight %; cabbage white (flakes) preferably in an amount of 0.6 to 2.2 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 3 to 10 weight %; celeriac preferably in an amount of 2 to 6 weight %; celery seeds powder preferably in an amount of 0.6 to 1.8 weight %; garlic preferably in an amount of 1 to 3 weight %; Onion, white, dried, (powder, minced) preferably in an amount of 3 to 9 weight %; peas preferably in an amount of 3 to 10 weight %; potato preferably in an amount of 6 to 20 weight %; quinoa preferably in an amount of 8 to 23 weight %; rice flour preferably in an amount of 7 to 22 weight %; salt (reg., kosher, sea salt) preferably in an amount of 2 to 7 weight %; savoy cabbage preferably in an amount of 3 to 10 weight %; spinach (leaf, powder) preferably in an amount of 0.7 to 2.2 weight %; turmeric preferably in an amount of 0.6 to 1.8 weight %; yeast extract preferably in an amount of 3 to 10 weight %; and zucchini (powder, diced) preferably in an amount of 1 to 5 weight %.

[0054] In a refinement, the bean-containing minestrone soup composition includes white beans (e.g., great northern beans), great tea extract, optionally cabbage, and optionally potatoes. In a refinement, the bean-containing minestrone soup composition includes beans (great northern) preferably in an amount of 3 to 10 weight %; cabbage white (flakes) preferably in an amount of 2 to 8 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 2 to 8 weight %; celery preferably in an amount of 1 to 4 weight %; green tea extract preferably in an amount of 0.02 to 0.06 weight %; inulin preferably in an amount of 2 to 10 weight %; leeks (granules -10+40) preferably in an amount of 2 to 7 weight %; oil (olive) preferably in an amount of 2 to 7 weight %; onion (powder, minced) preferably in an amount of 2 to 7 weight %; parsley preferably in an amount of 0.2 to 1 weight %; peas preferably in an amount of 3 to 9 weight %; potato preferably in an amount of 15 to 45 weight %; rice flour preferably in an amount of 6 to 18 weight %; salt preferably in an amount of 2 to 8 weight %; spinach (leaf, powder) preferably in an amount of 0.5 to 1.5 weight %; tomatoes (fruit powder, sun dried, granules) preferably in an amount of 2 to 7 weight %; and yeast extract preferably in an amount of 0.5 to 1.5 weight %.

[0055] In a refinement, the bean-containing minestrone soup composition includes brown beans, carrots, peas, potato, and rice flour. In another refinement, the bean-containing minestrone...
soup composition includes carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 4 to 14 weight %; celeriac preferably in an amount of 1 to 5 weight %; celery preferably in an amount of 0.5 to 1.6 weight %; leeks preferably in an amount of 2 to 8 weight %; oil (olive) preferably in an amount of 2 to 8 weight %; Onion, white, dried, (powder, minced) preferably in an amount of 3 to 10 weight %; parsley preferably in an amount of 0.5 to 1.5 weight %; peas preferably in an amount of 5 to 18 weight %; potato preferably in an amount of 8 to 24 weight %; rice flour preferably in an amount of 5 to 18 weight %; salt (reg., kosher, sea salt) preferably in an amount of 4 to 14 weight %; spinach (leaf, powder) preferably in an amount of 0.5 to 1.5 weight %; tomatoes, (fruit powder, sun dried granules) preferably in an amount of 0.9 to 2.8 weight %; turmeric preferably in an amount of 0.3 to 1.2 weight %; and yeast extract preferably in an amount of 0.5 to 1.5 weight %.

In a refinement, the pumpkin soup composition includes pumpkin, green tree extract, optionally rice flour, optionally carrots, and optionally brown rice powder. In a refinement, the pumpkin soup composition includes (new) includes brown rice powder (whole grain) preferably in an amount of 3 to 9 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 2 to 8 weight %; green tea extract preferably in an amount of 0.02 to 0.06 weight %; inulin preferably in an amount of 2 to 10 weight %; oil (olive) preferably in an amount of 1 to 7 weight %; onion (powder, minced) preferably in an amount of 1.0 to 3 weight %; pumpkin powder preferably in an amount of 20 to 60 weight %; rice flour preferably in an amount of 15 to 45 weight %; salt preferably in an amount of 2 to 10 weight %; and yeast extract preferably in an amount of 0.3 to 1 weight %.

In a refinement, the first vegetable broth includes carrots, maltodextrin, celery, spinach, and tomatoes. In a refinement, the first vegetable broth includes carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 6 to 18 weight %; celery preferably in an amount of 3 to 10 weight %; garlic preferably in an amount of 3 to 10 weight %; maltodextrin preferably in an amount of 8 to 25 weight %; oil (canola) preferably in an amount of 0.5 to 2 weight %; onion (powder, minced) preferably in an amount of 6 to 18 weight %; parsley preferably in an amount of 3 to 10 weight %; potato preferably in an amount of 1 to 3 weight %; salt preferably in an amount of 7 to 21 weight %; spinach (leaf, powder) preferably in an amount of 3 to 10 weight %; tomatoes (fruit
powder, sun dried, granules) preferably in an amount of 6 to 18 weight %; and yeast extract preferably in an amount of 1 to 6 weight %.

[0058] In a refinement, the second vegetable broth (chicken flavoring) includes carrots, chicken flavoring, maltodextrin, celery, spinach, soy lecithin, and tomatoes. In a refinement, the second vegetable broth composition includes carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 3 to 10 weight %; celery preferably in an amount of 3 to 12 weight %; garlic preferably in an amount of 3 to 9 weight %; maltodextrin preferably in an amount of 8 to 25 weight %; oil (canola) preferably in an amount of 0.5 to 2 weight %; onion preferably in an amount of powder, minced) preferably in an amount of 3 to 10 weight %; potato preferably in an amount of 1 to 6 weight %; salt preferably in an amount of 8 to 25 weight %; soy lecithin preferably in an amount of 0.5 to 3 weight %; spinach (leaf, powder) preferably in an amount of 3 to 12 weight %; tomatoes (fruit powder, sun dried, granules) preferably in an amount of 6 to 18 weight %; xanthan gum preferably in an amount of 0.5 to 4 weight %; and yeast extract preferably in an amount of 4 to 12 weight %.

[0059] In a refinement, the energy drink composition includes glycerin preferably in an amount of 20 to 60 weight %; water (purified) preferably in an amount of 40 to 80 weight %.

[0060] In a refinement, the tea composition that includes spearmint includes spearmint leaves organic preferably in an amount of 70 to 100 weight %.

[0061] In a refinement, the tea composition that includes lemon and spearmint includes lemon myrtle organic preferably in an amount of 3 to 12 weight %; lemon peel organic preferably in an amount of 10 to 25 weight %; spearmint leaves organic preferably in an amount of 50 to 95 weight %.

[0062] In a refinement, the tea composition that includes hibiscus includes hibiscus tea leaves organic preferably in an amount of 80 to 100 weight %.

[0063] In a refinement, the algal oil composition includes schizocatium algae oil (DHA Omega-3) preferably in an amount of 80 to 100 weight %.
In a refinement, the nutrient replenishment composition (NR-1) includes beet root powder, calcium carbonate, carrots, collard leaf, kale leaf, and tomatoes. In a refinement, the nutrient replenishment composition (NR-1) includes ascorbic acid preferably in an amount of 1 to 3 weight %; beet root powder preferably in an amount of 6 to 20 weight %; beta carotene preferably in an amount of 0.05 to 0.15 weight %; calcium carbonate preferably in an amount of 6 to 20 weight %; carrot (dehydrated, puffed, powder, pieces) preferably in an amount of 6 to 20 weight %; cholecalciferol preferably in an amount of 0.00 weight %; chromium Picolinate preferably in an amount of 0.00 weight %; collard leaf powder preferably in an amount of 6 to 20 weight %; cupric sulfate preferably in an amount of 0.01 to 0.06 weight %; cyanocobalamin, 0.00; Dl-alpha tocopherol acetate preferably in an amount of 0.3 to 1 weight %; ferrous fumarate preferably in an amount of 0.2 to 1 weight %; folic acid preferably in an amount of 0.00 weight %; kale leaf preferably in an amount of 6 to 20 weight %; magnesium stearate preferably in an amount of 1 to 6 weight %; manganese sulfate preferably in an amount of 0.04 to 0.08 weight %; niacinamide preferably in an amount of 0.3 to 1 weight %; pantothenic acid preferably in an amount of 0.1 to 0.6 weight %; phytonadione preferably in an amount of 0.00 weight %; potassium iodine preferably in an amount of 0 weight %; pyridoxine HCl preferably in an amount of 0.03 to 1 weight %; riboflavin preferably in an amount of 0.02 to 0.1 weight %; sodium molybdate preferably in an amount of 0.00 weight %; sodium selenate preferably in an amount of 0.00 weight %; spinach (leaf, powder) preferably in an amount of 6 to 20 weight %; thiamine mononitrate preferably in an amount of 0.02 to 0.1 weight %; tomatoes (fruit powder, sun dried, granules) preferably in an amount of 6 to 20 weight %; tribasic calcium phosphate preferably in an amount of 0.5 to 2 weight %; and zinc oxide preferably in an amount of 0.2 to 0.8 weight %.

In a variation, the each of the components of the fasting mimicking diet package and therefore the fasting mimicking diet, is substantially gluten free (e.g., each component has less than 20 ppm gluten) or very low gluten (e.g., each component has 20-100 ppm). In other variations, each of the components are provided in a serving size from 20 to 60 g. In other variations, the nut-containing nutrition bar is provided in a serving size from 30 to 60 g; cocoa-containing nutrition bar is provided in a serving size from 15 to 40 g; the olive containing composition (sea salt version) in a serving size from 10 to 20 g; the olive containing composition (garlic version) in a serving size from 10 to 20 g; kale cracker composition is provides in a serving size from 30 to 60 g; In another
variation, the kale cracker compositions are provided in a serving size from 20 to 50 g; the vegetable soup compositions are provided in a serving size from 20 to 50 g; the mushroom soup compositions are provided in a serving size from 20 to 50 g; the tomato soup compositions are provided in a serving size from 20 to 50 g; the bean-containing minestrone soup compositions are provided in a serving size from 20 to 50 g; the quinoa-containing minestrone soup compositions are provided in a serving size from 20 to 50 g; the pumpkin soup compositions are provided in a serving size from 20 to 50 g; the first vegetable both compositions are provided in a serving size from 5 to 15; the second vegetable both compositions are provided in a serving size from 3 to 15; and Energy Drink composition is provided in serving size of 1 to 5 oz.

[0066] The following examples illustrate the various embodiments of the present invention. Those skilled in the art will recognize many variations that are within the spirit of the present invention and scope of the claims.

[0067] Here we show that the fasting mimicking diet (FMD) as an intensive but brief form of a dietary intervention that can alter the numerical and functional profiles of innate and adaptive immunity and levels of circulating cytokines which are key therapeutic targets of majority of autoimmune (Table 1) in addition to promoting intestinal regeneration.

[0068] We show that cycles of FMD can alleviate the gastrointestinal autoimmune/inflammatory family of diseases called inflammatory bowel disease (IBD, Crohn's disease and ulcerative colitis; Fig. 1 and Table 2) by reducing the number of circulating innate immunity (macrophages and dendritic cells; Table 4), and T lymphocytes (Th1 and Th17; Table 5) while increasing anti-inflammatory CD4+T regulatory cells (Treg; Table 5). FMD cycles reduces pro-inflammatory cytokines related to autoimmune disease (IFN-γ and IL-17; Table 6) while increasing anti-inflammatory cytokine (IL-10; Table 6). Furthermore, FMD induces production of endogenous glucocorticoid levels (Fig. 2), which are known to play an important role as anti-inflammatory and immunosuppressive effects. This high efficiency, broad effects on both innate and adaptive immune response with minimal initial requirements and long-term safety/benefits allow this invention to incorporate into various types of therapy, including biological and pharmaceutical therapies. We also show that the cycles of FMD promote the growth of the intestine after it is shortened upon IBD induction (Table 3). The regenerative effects of the FMD cycles on various
stem cells in both mice and humans of pancreatic, hematopoietic, liver, and neural cells, indicate that FMD cycles can promote intestinal regeneration. Overall, the FMD cycles poses a great potential in both preventive and treatments for gastrointestinal autoimmune/inflammatory diseases, demonstrated here in inflammatory bowel disease model that includes both Crohn's disease and ulcerative colitis. With no need for invasive approach, it can benefit the conventional immunoregulatory approach in the way that directly regulates the dendritic cells, macrophages, and B-T lymphocyte populations and/or may indirectly change the cytokines or hormones to ameliorate the inflammatory autoimmune insults. Compared to established therapies against IBDs, this represents the first therapy that 1) causes a coordinated reduction in inflammation/autoimmune which return to the normal immune cell levels after re-feeding, and 2) causes regeneration and healing of the damaged tissue.

[0069] As 120-hr fasting is extremely difficult for human subjects to achieve due to the low compliance and the side-effects of malnutrition. The present invention makes use of a previously identified FMD tested in both animal studies and clinical trials (U.S. Pat. Appl. No. 14/178,953) which maximize the micronutrient contents, while providing a sufficient level of calories without interfering with the effects of fasting on the modulation of the immune and gastrointestinal systems.

[0070] Cycles of a FMD reduced dendritic cell, macrophages, B-lymphocytes, CD4+ Th1 and CD4+ Thl7 cell populations while increase anti-inflammatory regulatory T cells. Furthermore, FMD treatment reduces pro-inflammatory cytokines (TNF-γ and IL-17) while it increases anti-inflammatory cytokine (IL-10) and hormone (glucocorticoid). FMD cycles caused regeneration in the intestine damaged by the IBD. FMD treatments alleviated the symptoms in the mouse models of inflammatory bowel disease.

[0071] The experimental mouse FMD is based on a nutritional screen that identified ingredients which allow high nourishment during periods of low calorie consumption. The FMD diet consists of two different components designated as day 1 diet and day 2-3 diet that were fed in this order respectively. Day 1 diet contains 7.87 kJ/g, the day 2-3 diet is identical on all feeding days and contains 1.51 kJ/g. Day 1 and day 2-3 diets were supplied to the FMD cohort with the average intake of the ad lib control group (~4 g) every two weeks. On average, mice consumed 11.07 kJ (plant-based protein 0.75 kJ, carbohydrate 5.32 kJ, fat 5 kJ) on each day of the FMD regimen. Mice
consumed all the supplied food on each day of the FMD regimen and showed no signs of food aversion.

[0072] We supplied TD.7912 chow ad lib for 4 to 7 days after the end of the day 2-3 diet. The duration of FMD and that of refeeding with TD.7912 may be adjusted by the body weight loss (<20%) and recovery (>95%). Prior to supplying the FMD diet, animals were transferred into fresh cages to avoid feeding on residual chow and coprophagy.

[0073] The modified human FMD will substitute a subject's normal diet for a period of 5 days:

[0074] Diet 1: the FMD will substitute a subject's normal diet for a period of 5 days every 2-12 weeks depending on the need of the subject in terms of body weight and disease risk factor management. For day 1, the FMD will provide 4.5-7 kcal per pound of body weight (or 10-16 kcal per kilogram body weight). For days 2-5, the FMD will provide 3-5 kcal per pound of body weight (or 7-11 kcal per kilogram body weight). The day 1 diet should contain less than 30 grams of sugar, less than 28 grams of protein, 20-30 grams of monounsaturated fats, 6-10 grams of polyunsaturated fats and 2-12 grams of saturated fats. The Day 2-5 diets should contain less than 20 grams of sugar, less than 18 grams of protein, 10-15 grams of monounsaturated fats, 3-5 grams of polyunsaturated fats and 1-6 grams of saturated fats. The diet will also provide micronutrients at greater than 25% of the Daily Value (DV). In an alternative method the diet can be administered for only 1 day with a frequency of at least 1 day/week every week of the month.

[0075] Diet 2: Diet 2: the FMD will substitute a subject's normal diet for a period of 2 days every week. The FMD will provide 3-5 kcal per pound of body weight (or 7-11 kcal per kilogram body weight). The day 1 diet should contain less than 30 grams of sugar, less than 28 grams of protein, 20-30 grams of monounsaturated fats, 6-10 grams of polyunsaturated fats and 2-12 grams of saturated fats. The day 2 diet should contain less than 20 grams of sugar, less than 18 grams of protein, 10-15 grams of monounsaturated fats, 3-5 grams of polyunsaturated fats and 1-6 grams of saturated fats. The diet will also provide micronutrients at greater than 25% of the Daily Value (DV).

[0076] While exemplary embodiments are described above, it is not intended that these embodiments describe all possible forms of the invention. Rather, the words used in the
specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit and scope of the invention. Additionally, the features of various implementing embodiments may be combined to form further embodiments of the invention.

References:


WHAT IS CLAIMED IS:

1. A method for treating autoimmune and/or inflammatory disease, the method comprising:
   a) administering a fasting mimicking diet (FMD) to the subject for a first time period to a subject having a gastrointestinal autoimmune and/or inflammatory disease.

2. The method of claim 1 wherein the hypocaloric or calorie free diet or fasting mimicking diet is administered for a period of 5 days every 2-12 weeks.

3. The method of claim 1 wherein step b) is repeated a plurality of times at predetermined intervals.

4. The method of claim 3 wherein step b) is repeated at intervals from one week to 6 months.

5. The method of claim 3 wherein the subject is administered a normal diet in between repetition of step b).

6. The method of claim 1 wherein the FMD provides 4.5-7 kcal per pound of body weight (or 10-16 kcal per kilogram body weight).

7. The method of claim 1 wherein on day 1, the FMD provides less than 30 grams of sugar, less than 28 grams of protein, 20-30 grams of monounsaturated fats, 6-10 grams of polyunsaturated fats and 2-12 grams of saturated fats.

8. The method of claim 7 wherein on days 2-5 the FMD provides less than 20 grams of sugar, less than 18 grams of protein, 10-15 grams of monounsaturated fats, 3-5 grams of polyunsaturated fats and 1-6 grams of saturated fats.
9. The method of claim 8 wherein the FMD also provides micronutrients at greater than 25% of the Daily Value (DV).

10. The method of claim 1 wherein the FMD is administered for only 1 day with a frequency of at least 1 day/week every week of the month.

11. The method of claim 1 wherein the FMD will substitute a subject's normal diet for a period of 2 days every week.

12. The method of claim 11 wherein the FMD provides 3-5 kcal per pound of body weight (or 7-1 1 kcal per kilogram body weight).

13. The method of claim 12 wherein the day 1 FMD diet contains less than 30 grams of sugar, less than 28 grams of protein, 20-30 grams of monounsaturated fats, 6-10 grams of polyunsaturated fats and 2-12 grams of saturated fats.

14. The method of claim 13 wherein the day 1 The day 2 diet should contain less than 20 grams of sugar, less than 18 grams of protein, 10-15 grams of monounsaturated fats, 3-5 grams of polyunsaturated fats and 1-6 grams of saturated fats.

15. The method of claim 8 wherein the FMD also provides micronutrients at greater than 25% of the Daily Value (DV).

16. A diet package for administering a fasting mimicking diet treat autoimmune and/or inflammatory disease, the diet package comprising:
   a first set of rations for a first diet to be administered for a predetermined time period to a subject with administration schedule, the first diet providing:
   less than 40 grams of sugar for day 1;
   less than 30 grams of sugar for days 2 to 5 and any remaining days;
   less than 28 grams of protein for day 1;
   less than 18 grams of protein for days 2 to 5 and any remaining days;
   20-100 grams of monounsaturated fats for day 1:
6-30 grams of polyunsaturated fats for day 1;
2-12 grams of saturated fats for day 1;
10-50 grams of monounsaturated fats for days 2 to 5 and any remaining days;
3-15 grams of polyunsaturated fats for days 2 to 5 and any remaining days;
1-12 grams of saturated fats for days 2 to 5, or any remaining days; and
a micronutrient composition on each day and any remaining days; and
instructions for administering the diet package to a subject for treating autoimmune and/or inflammatory disease, the instructions including the administration schedule.

17. The diet package of claim 16 wherein the fasting mimicking diet provides:
8-10 kcal per kilogram body weight for each diet day:
less than 30 grams of sugar for each diet day;
less than 18 grams of protein for each diet day; and
9-15 grams of monounsaturated fats for each diet day, 2.5-4.5 grams of polyunsaturated fats for each diet day and 1-5.5 grams of saturated fats for each diet day.

18. The diet package of claim 17 wherein the fasting mimicking diet provides:
5-8 kcal per kilogram body weight for each diet day;
less than 20 grams of sugar for each diet day;
less than 12 grams of protein for each diet day; and
6.5-10 grams of monounsaturated fats for each diet day, 2.5-4.5 grams of polyunsaturated fats for each diet day and 1.5-4 grams of saturated fats for each diet day.

19. The diet package of claim 17 wherein the fasting mimicking diet provides:
0-3 kcal per kilogram body weight for each diet day;
less than 5 grams of sugar for each diet day;
less than 3 grams of protein for each diet day; and
less than 2.5 grams of monounsaturated fats for each diet day, less than 1 grams of polyunsaturated fats for each diet day and less than 1 grams of saturated fats for each diet day.
20. The diet package of claim 17 further comprising a second set of rations for a second
diet to be administered to the subject for a second time period, the second diet providing an overall
calorie consumption that is within 10 percent of a subject's normal calorie consumption for 25 to 26
days following the first diet.

21. The diet package of claim 17 wherein the first set of rations provide 400-800 mg of
calculator per day for days 1-5; 7.2-14.4 mg of iron per day for days 1-5; 200-400 mg of magnesium
per day for days 1-5; 1-2 mg of copper per day for days 1-5; 1-2 mg of manganese per day for days
1-5; and 3.5-7 mg of selenium per day for days 1-5.

22. The diet package of claim 17 wherein the first set of rations provide 2-4 mg of
Vitamin B1 per day for days 1-5; 2-4 mg of Vitamin B2 per day for days 1-5; 20-30 mg of Vitamin
B3 per day for days 1-5; 1-1.5 mg of Vitamin B5 per day for days 1-5; 2-4 mg of Vitamin B6 per
day for days 1-5; 240-480 mg of Vitamin B9 per day for days 1-5; 600-1000 IU of Vitamin D per
day for days 1-5; 14-30 mg of Vitamin E per day for days 1-5; over 80 mg of Vitamin K per day for
days 1-5; and 16-25 mg Vitamin D12 are provided during the predetermined time period.

23. The diet package of claim 17 wherein the first set of rations provides 600 mg of
Docosahexaenoic acid (DHA, algae-derived) during the predetermined time period.

24. The diet package of claim 17 further comprising a component having Vitamin A in an
amount of 900-1600 IU; Ascorbic Acid in an amount of 10-20 mg; calcium carbonate in an amount
of 60-100 mg; ferrous fumarate in an amount of 3-6 mg; cholecalciferol in an amount of 0.001-0.005
mg; dl-alpha tocopheryl acetate in an amount 3-7 mg; phytonadione in an amount of 0.1-0.04 mg;
thiamine mononitrate in an amount of 0.15-0.5 mg; riboflavin in an amount 0.2-0.6 mg; and
niacinamide in an amount of 3-7mg.

25. The diet package of claim 24 further comprising a component having calcium
pantothenate in an amount of 1.5-4.0 mg; pyridoxine hydrochloride in an amount of 0.3-0.7 mg;
biotin in an amount of 0.01-0.02 mg; folic acid in an amount of 0.07-0.14 mg; cyanocobalamin in an
amount of 0.001-0.002 mg; chromium picolinate in an amount of 0.014-0.022 mg; cupric sulfate in
an amount of 0.18-0.32 mg; potassium iodide in an amount of 0.03-0.045 mg; magnesium oxide in an amount of 20-32 mg; manganese sulfate of 0.3-0.7 mg; sodium molybdate in an amount of 0.014-0.023 mg; sodium selenate in an amount of 0.014-0.023 mg; and zinc oxide in an amount of 3-5 mg.
<table>
<thead>
<tr>
<th>% of fecal bleeding</th>
<th>Control Diet</th>
<th>FMD</th>
</tr>
</thead>
<tbody>
<tr>
<td>40%</td>
<td>0%</td>
<td></td>
</tr>
</tbody>
</table>

**FIG. 1**

**FIG. 2**
<table>
<thead>
<tr>
<th>Diseases</th>
<th>Pathogenesis</th>
<th>Innate Immunity</th>
<th>Adaptive immunity</th>
<th>Cytokines</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Macrophage</td>
<td>Dendritic Cells</td>
<td>B-cells</td>
</tr>
<tr>
<td>Inflammatory Bowel Disease</td>
<td>Chronic inflammation of the gastrointestinal tract, characterized by macrophage and B/T-cell accumulation mainly in the terminal ileum.</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Crohn's disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory Bowel Disease</td>
<td>Chronic mucosal inflammation from the rectum to a varying degree, characterized by neutrophil, B/T-cell infiltration in which superficial mucosal ulceration develops.</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ulcerative Colitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irritable Bowel Syndrome</td>
<td>A chronic, but low-grade, autoimmune activation mediated by macrophage and B/T-cell mediated of GI nerves.</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Celiac Disease</td>
<td>T-cell mediated destruction of the intestinal epithelium following the ingestion of dietary gluten.</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Microscopic Colitis (collagenous</td>
<td>Hyper immune response mediated by B/T-cell infiltration in the colonic mucosa</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>and lymphocytic colitis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behcet Disease</td>
<td>T-cell mediated immune response characterized by recurrent oral aphthous ulceration, genital ulceration, skin lesions and uveitis</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>FMD Treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. FMD-altered both innate and adaptive immune response and cytokines as therapeutic targets for treating major gastrointestinal autoimmune/inflammatory diseases.

+ indicates an 'increase', indicates a 'decrease', and n/a indicates 'no change'

**FIG. 3**
Table 2. FMD prevent DSS-induced colon shortening.

<table>
<thead>
<tr>
<th></th>
<th>Colon Length (Mean± STD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naïve (No DSS Treatment)</td>
<td>8.09±1.24</td>
</tr>
<tr>
<td>DSS Treatment – Control Diet (DSS CD)</td>
<td>6.12±0.82</td>
</tr>
<tr>
<td>DSS Treatment – Fasting Mimicking Diet (DSS FMD)</td>
<td>7.43±1.17</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naïve vs. DSS CD</td>
<td>***</td>
</tr>
<tr>
<td>Naïve vs. DSS FMD</td>
<td>ns</td>
</tr>
<tr>
<td>DSS CD vs. DSS FMD</td>
<td>*</td>
</tr>
</tbody>
</table>

*** p< 0.001
*  p< 0.05

FIG. 4

Table 3. FMD causes colon regeneration.

<table>
<thead>
<tr>
<th></th>
<th>Colon Length (Mean± STD)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSS Treatment – Control Diet (DSS CD)</td>
<td>6.12±0.82</td>
<td>*</td>
</tr>
<tr>
<td>DSS Treatment – Fasting Mimicking Diet (DSS FMD)</td>
<td>7.43±1.17</td>
<td></td>
</tr>
</tbody>
</table>

*  p< 0.05

FIG. 5
Table 4. FMD reduces circulating dendritic cell number.

<table>
<thead>
<tr>
<th>Dendritic Cells</th>
<th>% Splenocyte (Mean± STD)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSS Treatment – Control Diet (DSS CD)</td>
<td>3.65 ± 1.23</td>
<td>*</td>
</tr>
<tr>
<td>DSS Treatment – Fasting Mimicking Diet</td>
<td>1.58 ± 0.44</td>
<td></td>
</tr>
<tr>
<td>(DSS FMD)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Macrophage</th>
<th>% Splenocyte (Mean± STD)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSS Treatment – Control Diet (DSS CD)</td>
<td>1.33 ± 0.64</td>
<td>P = 0.09</td>
</tr>
<tr>
<td>DSS Treatment – Fasting Mimicking Diet</td>
<td>0.675 ± 0.19</td>
<td></td>
</tr>
<tr>
<td>(DSS FMD)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* p< 0.05

**FIG. 6**

Table 5. FMD reduces adaptive immune response

<table>
<thead>
<tr>
<th></th>
<th>Control Diet Treatment</th>
<th>FMD Treatment</th>
<th>Significant</th>
<th>FMD Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B Lymphocytes</strong></td>
<td>77.8±6.8</td>
<td>62.8±9.3</td>
<td>p &lt; 0.05</td>
<td>↓</td>
</tr>
<tr>
<td><strong>Th 1</strong></td>
<td>2974.4±708.0</td>
<td>805.8±251.5</td>
<td>p &lt; 0.05</td>
<td>↓</td>
</tr>
<tr>
<td><strong>Th 17</strong></td>
<td>2535.9±722.0</td>
<td>432.4±117.4</td>
<td>p &lt; 0.05</td>
<td>↓</td>
</tr>
<tr>
<td><strong>Regulatory T cells</strong></td>
<td>13.6±4.21</td>
<td>25.10±4.20</td>
<td>p &lt; 0.01</td>
<td>↑↑</td>
</tr>
</tbody>
</table>

**FIG. 7**
Table 6. FMD reduces autoimmune-associated cytokine production (IFN-γ, IL-17 and increases an anti-inflammatory cytokine production (IL-10).

<table>
<thead>
<tr>
<th></th>
<th>Control Diet Treatment</th>
<th>FMD Treatment</th>
<th>Significant</th>
<th>FMD Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFN-γ</td>
<td>558.4±124.5</td>
<td>296.0±83.4</td>
<td>p &lt; 0.001</td>
<td>↑↑↑</td>
</tr>
<tr>
<td>IL-17</td>
<td>36.8±9.7</td>
<td>20.8±4.2</td>
<td>p &lt; 0.01</td>
<td>↑↑</td>
</tr>
<tr>
<td>IL-10</td>
<td>6.5±1.3</td>
<td>8.5±0.5</td>
<td>p &lt; 0.05</td>
<td>↑</td>
</tr>
</tbody>
</table>

**FIG. 8**
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

A61K 31/70(2006.01)i, A61K 38/00(2006.01)i, A61K 31/51(2006.01)i, A61K 31/07(2006.01)i, A61K 31/20(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K 31/70; A23L 1/29; A61K 38/01; A61K 38/00; A61K 31/5377; A61K 31/51; A61K 31/07; A61K 31/20

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Korean utility models and applications for utility models
Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
eKOMPASS(KIPO internal) & Keywords: fasting mimicking diet, autoimmune disease, inflammatory disease, sugar, protein, monounsaturated fats, polyunsaturated fats, saturated fats, micronutrient

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 2015-0004280 Al (UNIVERSITY OF SOUTHERN CALIFORNIA) 01 January 2015 See paragraphs [0033], [0036], [0060]; Table 4.</td>
<td>16-25</td>
</tr>
<tr>
<td>X</td>
<td>Wow 2015-153850 A2 (UNIVERSITY OF SOUTHERN CALIFORNIA) 08 October 2015 See paragraphs [0036], [0046]; claims 1-21.</td>
<td>16-25</td>
</tr>
<tr>
<td>A</td>
<td>US 2014-0227373 Al (UNIVERSITY OF SOUTHERN CALIFORNIA) 14 August 2014 See the whole document.</td>
<td>16-25</td>
</tr>
<tr>
<td>A</td>
<td>US 2009-008427 Al (GLICKMAN, R. et al.) 02 April 2009 See the whole document.</td>
<td>16-25</td>
</tr>
<tr>
<td>A</td>
<td>US 2014-0274892 Al (MEAD JOHNSON NUTRITION (ASIA PACIFIC) PTE. LTD.) 18 September 2014 See the whole document.</td>
<td>16-25</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

Date of the actual completion of the international search 10 July 2017 (10.07.2017)

Date of mailing of the international search report 11 July 2017 (11.07.2017)

Name and mailing address of the ISA/KR
International Application Division
Korean Intellectual Property Office
189 Cheogra-ro, Seo-gu, Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer
CHO, Ki Yun
Telephone No. +82-42-481-5655

Form PCT/ISA/210 (second sheet) (January 2015)
Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-15
   because they relate to subject matter not required to be searched by this Authority, namely:
   Claims 1-15 pertain to methods for treatment of the human body by therapy, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.

2. ☐ Claims Nos.:  
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.: 
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☑ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☑ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.

3. ☑ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 

4. ☑ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 

Remark on Protest  
☒ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☒ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☒ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>US 2015-0004280 Al</strong></td>
<td>01/01/2015</td>
<td><strong>AU 2014-284399 Al</strong></td>
<td>28/01/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CA 2916459 Al</strong></td>
<td>08/01/2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CN 105431055 A</strong></td>
<td>23/03/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP 3016528 Al</strong></td>
<td>11/05/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>JP 2016-525091 A</strong></td>
<td>22/08/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>KR 10-2016-0030211 A</strong></td>
<td>16/03/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 2017-0000183 Al</strong></td>
<td>05/01/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 9386790 B2</strong></td>
<td>12/07/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>WO 2015-002972 Al</strong></td>
<td>08/01/2015</td>
</tr>
<tr>
<td><strong>WO 2015-153850 A2</strong></td>
<td>08/10/2015</td>
<td><strong>AU 2015-240720 Al</strong></td>
<td>20/10/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CA 2944479 Al</strong></td>
<td>08/10/2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP 3125904 A2</strong></td>
<td>08/02/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>KR 10-2017-0003542 A</strong></td>
<td>09/01/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 2017-027217 Al</strong></td>
<td>02/02/2017</td>
</tr>
<tr>
<td><strong>US 2014-0227373 Al</strong></td>
<td>14/08/2014</td>
<td><strong>AU 2014-216349 Al</strong></td>
<td>06/08/2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CA 2900782 Al</strong></td>
<td>21/08/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CN 105008929 A</strong></td>
<td>28/10/2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP 2936776 A2</strong></td>
<td>23/12/2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>JP 2016-509994 A</strong></td>
<td>04/04/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 2016-0331016 Al</strong></td>
<td>17/11/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 2017-0035094 Al</strong></td>
<td>09/02/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 9237761 B2</strong></td>
<td>19/01/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>WO 2014-127000 A2</strong></td>
<td>21/08/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 8957071 B2</strong></td>
<td>17/02/2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CA 2905817 Al</strong></td>
<td>25/09/2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>CN 105073126 A</strong></td>
<td>18/11/2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>EP 2968438 Al</strong></td>
<td>20/01/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>US 9289461 B2</strong></td>
<td>22/03/2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>WO 2014-150566 Al</strong></td>
<td>25/09/2014</td>
</tr>
</tbody>
</table>